Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTARCTIC: Tailored Prasugrel in Elderly ACS
NCT01538446Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prasugrel in acute coronary syndrome (ACS) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite of Cardiovascular death, myocardial infarction, stroke, urgent revascularisation, stent thrombosis and bleedings (BARC 2, 3 or 5) at 12 months. Started Mar 2012; status: completed.
02
Drugs
prasugrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01538446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01538446.